CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Rescue Combination for MRSA Pneumonia With Pneumothorax

Published: Wed, 27 Sep 2017 12:00:00 EDT
The authors describe a combination therapy for the successful treatment of a case of severe community-acquired MRSA pneumonia complicated by pneumothorax.
BMC Pulmonary Medicine

Aspirin Challenge and Desensitization: How, When and Why

Published: Fri, 22 Sep 2017 12:00:00 EDT
Learn which patients may safely undergo low-dose aspirin challenge/desensitization procedures.
Current Opinion in Allergy and Clinical Immunology

A 19-Year-Old Woman With Abdominal Pain and Diarrhea

Published: Fri, 22 Sep 2017 12:00:00 EDT
A 19-year-old woman presents due to fevers, nausea, severe abdominal pain, and watery diarrhea. The symptoms have been on-and-off over the past few months. What treatment is indicated?
Osmosis
Displaying results 1-3 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

EuroBiotech Report—Bavarian Nordic, Nabriva, Immunocore, Glythera-Iontas and Sanofi

Published: Thu, 21 Sep 2017 13:39:03 +0000
In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more. 

Celgene-backed FLX picks CCR4 antagonist for clinical trials

Published: Thu, 21 Sep 2017 13:10:06 +0000
FLX Bio has picked a clinical candidate from its CCR4 antagonist program. The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.

Janssen deal gives new kid in town Provention two immune candidates

Published: Thu, 21 Sep 2017 12:05:14 +0000
Right on the heels of a $28 million seed financing, Provention Bio has snapped up two inflammatory bowel disease candidates from Janssen that should make it a double clinical-stage biotech next year.
Displaying results 1-3 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top